Home >Deals & Matter Corner>Deal>JSA advises Zydus Hospitals and Healthcare Research Private Limited on its acquisition of VINS Hospital

JSA advises Zydus Hospitals and Healthcare Research Private Limited on its acquisition of VINS Hospital

Deal
January 22, 2026

JSA Advocates & Solicitors (JSA) advised and assisted Zydus Hospitals and Healthcare Research Private Limited, an affiliate of the Zydus Group, in its 100% acquisition of Vadodara Institute of Neurological Sciences (VINS) Hospital, a prominent neurological care hospital located in Vadodara.

Through this acquisition, Zydus aims to establish one of India’s most comprehensive centres for advanced neuroscience by combining the specialised expertise of VINS, a dedicated 50-bed facility, with the extensive resources of Zydus’s 300-bed multispecialty and cancer care hospital in Vadodara.

The transaction was led by Rajul Bohra, Lead Partner, Saurabh Sharma, Partner; and Associates, Anmol Khurana and Tanishq Sharma from JSA’s Mergers & Acquisitions team.

POST TAGS

Tags Corporate Healthcare Deals, Healthcare Consolidation, Healthcare Growth India, Healthcare M&A India, Hospital Acquisition India, Indian Healthcare Sector, JSA Deal Update, Life Sciences Law, M&A Legal Advisory, Medical Infrastructure India, Multispecialty Hospitals, Neurology Healthcare India, Strategic Healthcare Investment, VINS Hospital Vadodara, Zydus Hospitals

Rajul Bohra Partner

Rajul specializes in General Corporate Commercial, Mergers & Acquisitions, Domestic & Cross Border Investments, Corporate Restructuring and Compliance, Employment and Anti-Corruption & Investigation.

Saurabh Sharma Partner

Saurabh Sharma, Partner at JSA, has over 14 years of experience in Corporate and M&A, Joint Ventures, and GIFT City practice. He advises leading Indian and multinational corporations, private equity investors, and financial institutions on high-value transactions, corporate restructurings, and regulatory frameworks. His expertise spans fintech, digital lending, tokenisation, infrastructure, and cross-border investments, including advisory under IFSCA and RBI regulations.